VCI Global Limited has been engaged by a Fin-MedTech Medical Group (the ?Medical Group?) as its initial public offering (?IPO?) consultant for its intended IPO on Nasdaq which is expected to be completed in 2024/2025. The Medical Group offers personalised, predictive and preventive medicine through a digital wallet and digital twin, all within its proprietary Fin-MedTech single platform. This is done by integrating its expertise of financial, medical and digital transformation technologies.

Its mission is to empower behavioural revolution through data-driven innovations. Under this engagement, VCI Global will provide consultancy services in equity structure and capital market strategy, facilitate engagements of external professionals namely underwriter, auditor and lawyer; assists in regulatory approval and provide recommendations in compliance and internal control matters. VCI Global will receive payment in shares throughout the engagement exercise.

Subsequently, the estimated income, to be derived from this consultancy service, is in the range of USD 4 million to USD 8 million, pending the IPO valuation.